title: Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases.
abstract: OBJECTIVE
  To study those conditions with a proven or hypothesised immunologic pathogenesis and denominated under a working definition of undifferentiated connective tissue diseases (UCTD).
  
  
  METHODS
  A multicentre prospective study was organised involving 10 tertiary referral centers of internal medicine in Italy, with the aim of describing the natural history of UCTD and the prevalence of its different clinical and immunological manifestations.
  
  
  RESULTS
  After a five-year follow-up period, data on 165 patients were available for analysis. UCTDs occur mainly in females in their fourth decade of life. Articular and mucocutaneous features and Raynaud's phenomenon represent the most common findings. Nevertheless, we also detected a relatively high incidence of permanent major organ damage. Regarding the immunologic parameters, we documented some conflicting results in the correlation between serologic abnormalities and clinical features. In 10 patients UCTD evolved to a major disease, generally systemic lupus erythematosus or Sjögren's syndrome.
  
  
  CONCLUSIONS
  A low rate of evolution to a defined autoimmune disease, the limited use of steroid or immunosuppressive therapy, and a favourable course in the majority of cases are the main characteristics of patients with UCTDs.
authors.affiliation: Istituto di Clinica Medica, Ematologia ed Immunologia Clinica, Università di Ancona. eleonora@popcsi.unian.it
authors.forename: M G
authors.initials: MG
authors.lastname: Danieli
authors.forename: P
authors.initials: P
authors.lastname: Fraticelli
authors.forename: F
authors.initials: F
authors.lastname: Franceschini
authors.forename: R
authors.initials: R
authors.lastname: Cattaneo
authors.forename: A
authors.initials: A
authors.lastname: Farsi
authors.forename: A
authors.initials: A
authors.lastname: Passaleva
authors.forename: M
authors.initials: M
authors.lastname: Pietrogrande
authors.forename: F
authors.initials: F
authors.lastname: Invernizzi
authors.forename: M
authors.initials: M
authors.lastname: Vanoli
authors.forename: R
authors.initials: R
authors.lastname: Scorza
authors.forename: M G
authors.initials: MG
authors.lastname: Sabbadini
authors.forename: R
authors.initials: R
authors.lastname: Gerli
authors.forename: A
authors.initials: A
authors.lastname: Corvetta
authors.forename: G
authors.initials: G
authors.lastname: Farina
authors.forename: F
authors.initials: F
authors.lastname: Salsano
authors.forename: R
authors.initials: R
authors.lastname: Priori
authors.forename: G
authors.initials: G
authors.lastname: Valesini
authors.forename: G
authors.initials: G
authors.lastname: Danieli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000974:Antibodies, Antinuclear / Q000032:analysis; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D003240:Connective Tissue Diseases / Q000188:drug therapy* / Q000276:immunology*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011928:Raynaud Disease / Q000188:drug therapy / Q000276:immunology; D013256:Steroids; D016896:Treatment Outcome; D014657:Vasculitis / Q000188:drug therapy / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D000974:Antibodies, Antinuclear; D013256:Steroids